> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-100/
- Published: 2017-08-20T12:00:00.000Z
- Updated: 2026-09-14T22:42:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139427

**Alvogen** has signed a definitive agreement to acquire **Omega Bittner**, a Russia-based pharmaceutical firm owned by *Perrigo*. Omega Bittner markets over-the-counter products in Russia, including Lactacyd, Aflubin and Paranit. Alvogen says the acquisition supports its strategy to gain more exposure to Russia’s high growth market. It will also create greater scale and diversity across its portfolio and sales channels.

**RedHill Biopharma** has entered into a commercialization agreement with **ParaPRO**, an Indiana-based specialty pharmaceutical company, granting RedHill the exclusive rights to promote esomeprazole strontium delayed-release capsules to gastroenterologists in certain U.S. territories. The prescription proton pump inhibitor is indicated for adults for treating gastroesophageal reflux disease.

Clear orthodontic corrective device maker **ClearCorrect** has agreed to be acquired by **Straumann Holding** for about $150 million. ClearCorrect says the acquisition will allow it to improve and expand the global reach of its Flex and Unlimited treatments.